The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27119626 |
18 |
Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex. |
University of Cambridge |
27115555 |
6 |
Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit. |
Pfizer |
26572217 |
60 |
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors. |
Genentech |
25799074 |
65 |
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. |
Glaxosmithkline |
26230603 |
176 |
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors. |
Glaxosmithkline |
26080064 |
141 |
Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. |
University of Michigan |
24144283 |
100 |
Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. |
Icahn School of Medicine At Mount Sinai |
27757418 |
27 |
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia. |
University of Oxford |
26702435 |
6 |
Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance. |
University of Oxford |
32453591 |
70 |
Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. |
University of Illinois At Chicago |
27219867 |
94 |
Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. |
Genentech |
30606676 |
83 |
Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor. |
Gilead Sciences |
30339381 |
32 |
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers. |
Novartis Institutes For Biomedical Research |
29656650 |
151 |
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. |
University of Strathclyde |
29169673 |
115 |
Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300. |
Wuxi Apptec |
28463487 |
185 |
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. |
University of Michigan |
30015487 |
96 |
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. |
TBA |
28268136 |
130 |
Methylpyrrole inhibitors of BET bromodomains. |
Abbvie |
28949521 |
88 |
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor. |
Abbvie |